Copyright
©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Aug 27, 2021; 13(8): 853-867
Published online Aug 27, 2021. doi: 10.4254/wjh.v13.i8.853
Published online Aug 27, 2021. doi: 10.4254/wjh.v13.i8.853
Kidney transplant from donors with hepatitis B: A challenging treatment option
Praopilad Srisuwarn, Vasant Sumethkul, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand
Author contributions: Srisuwarn P and Sumethkul V outlined the scope; Srisuwarn P collected the information; Srisuwarn P and Sumethkul V wrote, read and final approval the manuscript.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Vasant Sumethkul, FACP, FRCP (Hon), MD, Full Professor, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama 6 Road, Ratchathewi, Bangkok 10400, Thailand. vasant.sum@mahidol.ac.th
Received: February 24, 2021
Peer-review started: February 24, 2021
First decision: June 4, 2021
Revised: June 22, 2021
Accepted: July 29, 2021
Article in press: July 29, 2021
Published online: August 27, 2021
Peer-review started: February 24, 2021
First decision: June 4, 2021
Revised: June 22, 2021
Accepted: July 29, 2021
Article in press: July 29, 2021
Published online: August 27, 2021
Core Tip
Core Tip: Low-risk hepatitis B surface antigen (HBsAg) positive kidney donor, defined by a negative test of hepatitis B virus (HBV) DNA being allocated to immune-recipients with anti-HBs at least 10 mIU/mL is a key factor in overcoming the risk of HBV transmission. The risk may be further eliminated with optimal nucleos(t)ide analog prophylaxis. Blood tests for HBV DNA, HBs Ag, and liver function tests should be routinely monitored after transplantation and when there is a change of immunosuppression. The excellent long-term outcomes being reported suggested that the outcomes of this treatment option are promising. This will lead to broader use of organs with positive HBsAg.